Clinical Biostatistics & Data Analysis

Multiplicity in Platform, Basket and Umbrella Trials Multiplicity in Platform, Basket and Umbrella Trials Multiplicity in clinical trials presents a unique challenge, particularly within the frameworks of platform, basket, and umbrella studies. Understanding how to manage these challenges is vital for ensuring regulatory compliance and scientific integrity. This guide presents a comprehensive tutorial for clinical…

Read More “Multiplicity in Platform, Basket and Umbrella Trials” »

Graphical Approaches to Multiple Testing in Modern Trial Designs Introduction to Multiple Testing in Clinical Trials Multiple testing in clinical trials is a rigorous and essential component of biostatistical analysis that helps ensure the integrity and reliability of trial outcomes. When conducting clinical trials, the primary goal is to establish the efficacy and safety of…

Read More “Graphical Approaches to Multiple Testing in Modern Trial Designs” »

Pre-Specifying Subgroup Analyses in Protocol and SAP for Regulatory Trust In the realm of clinical research, the rigorous evaluation of treatments through patient enrollment in clinical trials is paramount for evidence-based decision-making. One critical aspect that demands careful consideration is the pre-specification of subgroup analyses in the clinical trial protocol and the statistical analysis plan…

Read More “Pre-Specifying Subgroup Analyses in Protocol and SAP for Regulatory Trust” »

Multiplicity Considerations in Real-World Evidence and External Controls Introduction to Multiplicity in Clinical Trials Clinical trials are crucial for developing safe and effective therapies, particularly for conditions like ankylosing spondylitis. However, the evaluation of clinical data can become complex due to multiplicity issues. Multiplicity refers to the problem that arises when multiple comparisons or endpoints…

Read More “Multiplicity Considerations in Real-World Evidence and External Controls” »

Handling Biomarker-Defined Subgroups and Companion Diagnostics in Clinical Trials In the ever-evolving landscape of clinical trials, understanding how to effectively manage biomarker-defined subgroups and companion diagnostics is crucial. This step-by-step tutorial provides essential guidance for clinical operations, regulatory affairs, and medical affairs professionals in the US, UK, and EU. The focus will be on the…

Read More “Handling Biomarker-Defined Subgroups and Companion Diagnostics” »

Subgroup Analyses in Rare Disease and Small Population Trials Subgroup Analyses in Rare Disease and Small Population Trials Subgroup analyses are critical components of clinical trials that allow researchers to explore treatment effects among predefined patient subsets. Particularly in rare disease and small population trials, where sample sizes limit statistical power, the insights derived from…

Read More “Subgroup Analyses in Rare Disease and Small Population Trials” »

Integrating Multiplicity Controls With Interim Analyses and Estimands Integrating Multiplicity Controls With Interim Analyses and Estimands In the realm of clinical trials, particularly in regulatory environments such as those governed by the FDA, EMA, and MHRA, the design and analysis of studies have become increasingly sophisticated. Specifically, the intertwining of multiplicity controls with interim analyses…

Read More “Integrating Multiplicity Controls With Interim Analyses and Estimands” »

Case Studies: Multiplicity Pitfalls That Undermined Trial Conclusions Case Studies: Multiplicity Pitfalls That Undermined Trial Conclusions The complexity of clinical trials often leads to challenges associated with multiplicity, which can significantly impact the reliability of trial conclusions. In this tutorial, we provide detailed case studies that exemplify these pitfalls, particularly centered around the lecanemab clinical…

Read More “Case Studies: Multiplicity Pitfalls That Undermined Trial Conclusions” »